

# Antagonistic Activity of *Lactobacillus Casei* Against Bacterial Genera Isolated From Patients With Renal Failure and Acute Urinary Tract Infections

Zainab H Ridha<sup>\*1</sup>, Ali A. Al-Hisnawi<sup>2</sup>, Ahmed N. AL-Mussawy<sup>3</sup>

<sup>1</sup> Department of Biology, College of Sciences, University of Karbala, Karbala, Iraq, email: zh6821889@gmail.com

<sup>2</sup> Department of Biology, College of Sciences, University of Karbala, Karbala, Iraq, email: ali.alhisnawi@uokerbala.edu.iq

<sup>3</sup> Department of Biology, College of Sciences, University of Karbala, Karbala, Iraq, email: ahmed.issa@uokerbala.edu.iq

## Abstract

**Background:** Urinary tract infections are one of the most common bacterial infections globally. Given that the progression of UTIs may be directly linked to recurrent infections, the progression to acute kidney infection and chronic kidney disease is possible. **Objective:** Antagonistic activity of *Lactobacillus casei* against multidrug bacteria isolated from patients with renal failure. **Methodology:** A total of 208 urine samples were collected, identified, and tested for antimicrobial susceptibility using VITEK 2. DNA from isolates was extracted, employed to detect genes encoding beta-lactamase enzymes genes (bla SHV, bla TEM, bla CTX-M, and qnrA) in the studied bacterial isolates and antagonism activity of *Lactobacillus casei* against bacterial pathogens isolated from renal failure and acute UTIs. **Results:** cultivated samples showed that 124 bacterial isolates were identified and distributed into 83 (66.94%) from acute UTIs and 41(33.06%) from renal failure disease. Susceptibility testing results revealed that *P. aeruginosa* isolates were the most resistant to carbapenems, whereas *E. coli* isolates were completely susceptible. Using polymerase chain reaction, genes encoding resistance genes were found to be carried. On the other hand, *L. casei* isolates from cheese and Activia revealed high inhibitory activity and ability to suppress the growth of multidrug-resistant clinical pathogens. **Conclusion:** *E. coli* is the most common bacterial cause of UTIs in renal failure patients, these pathogens exhibited of multidrug resistance, molecularly supported by their carrying a number of beta-lactamase enzyme genes. However, *L. casei*, which is isolated from natural sources, is highly effective at inhibiting multidrug bacteria.

**Keywords:** Antagonism, *L.casei*, multidrug bacteria, UTIs, renal failure,  $\beta$ -lactamase.

## INTRODUCTION

Urinary tract infections and interstitial nephritis are serious global health issues. Nephritis is characterized by both acute and chronic renal impairment; however, UTI is one of the most prevalent infections globally (Li et al., 2025). Urinary tract infections are microbial infections that impact the kidneys, bladder, ureters, and urethra, among other areas of the urinary system. Bacterial invasion and growth are the main causes of these illnesses (Putri et al., 2025). UTIs start when certain adhesions enable gut-resident uropathogens to colonize the urethra and then the bladder. Bacteria start to proliferate and produce toxins and enzymes that help them survive if the host's inflammatory response is unable to eradicate them altogether. If the pathogen penetrates the kidney epithelial barrier, further colonization of the kidneys may result in bacteremia (Zhou et al., 2023). Both Gram-positive and Gram-negative bacteria can cause UTIs, but the latter having the higher frequency rate of 74.4% of UTIs, *Escherichia coli* is the microbe that causes the majority of infections across all age groups and circumstances (Coutinho et al., 2021). They are deemed as causative agents of UTIs, with a consistent incidence of Gram-negative bacteria, in addition to *E. coli*, *Streptococcus agalactiae*, *Klebsiella* species, *Pseudomonas aeruginosa*, and *Staphylococcus saprophyticus* are all cause UTIs (Monroy-Higuera et al., 2026). Antibiotic microbial resistance is a well-established and expanding issue in global healthcare systems. The predicted number of excess fatalities in the next 35 years is at least 300 million. Multi-drug resistant species, such *E. coli* that produce Extended Spectrum Beta-Lactamase, are challenging to treat, which leads to longer hospital stays and higher mortality rates (Ong et al., 2021). ESBLs are enzymes having significant hydrolyzing activity on a wide range of  $\beta$ -lactam antibiotics, including oxyminocephalosporins and aztreonam Other  $\beta$ -lactamases, including as TEM-type, SHV-type and CTX-M-type  $\beta$ -lactamases, have been found in this species in addition to class C cephalosporinase (Mirkalantari et al., 2020).

It is generally known that the use of excessive antibiotic contributes to the emergence of antibiotic resistance in microorganisms (Habboush et al., 2023). As a result, from ancient times, people have used dairy and fermented foods, which have been a known source of lactic acid bacteria (Ibrahim et al., 2024). Through the use of probiotics, and supplements, interventional studies have shown the potential of gut microbiota modification in enhancing kidney function. In patients with chronic kidney disease, formulations including, *Lactobacillus casei*, and *Lactobacillus acidophilus* have been demonstrated to decrease uremic toxins, lower serum levels of indoxyl sulfate, and lessen microinflammation (Liu et al., 2025). By shifting the composition of

the gut microbiota in favor of advantageous taxa like Subdoligranulum, Bifidobacteria, and Lactobacillus, these treatments improve estimated glomerular filtration rate and lower eprotein levels (Młynarska et al., 2024 ). The current aimed to test the antagonism activity of Lactobacillus casei against multidrug bacteria isolated from patients with renal failure.

## METHODOLOG

### Collection specimens:

Between September 2025 to March 2026. 208 samples of urine were collected from patients who suffer from renal failure and acute UTIs at Imam Hussein Teaching Hospital and Imam Hassan Al-Mujtaba Teaching Hospital in Karbala city. Urine samples were collected from the aforementioned groups using sterile cups and transferred to the laboratory in a short time.

### Identification of bacterial isolates

Urine samples were cultured on the different media for isolating the UTI bacterial causative agents. Following culturing, all bacterial isolates were subjected to preliminary biochemical testing, which included growth. The VITEK 2 then used to accurately establish the identity of the bacteria isolates and the bacterial isolates were subjected to antibiotic susceptibility testing using the Vitek2 Compact System with the AST-GN222 card. All isolates were examined against 16 antibiotic agents related to 7 antibiotics classes.

### DNA extraction and PCR technique:

A bacterial genomic DNA extraction kit manufactured by Geneaid was used to extract DNA from the bacterial isolates that were identified. PCR was utilized to detect the presence of four significant genes associated with antibiotic resistance: blaCTX-M, blaSHV, blaTEM, and the quinolone resistance gene qnrA. The reaction products were run over a 1.5% agarose gel using specific primers.

**Table 1: The Reaction Conditions for each Tested Gene.**

| Gene.   | PCR step             | Temp. | Time   | No. Of cycles |
|---------|----------------------|-------|--------|---------------|
|         | Initial denaturation | 95    | 3 min  | 33 cycles     |
|         | Denaturation         | 94    | 30 sec |               |
| bla SHV | Annealing            | 57    | 33 sec |               |
| bla TEM |                      | 50    |        |               |
| CTX-M   |                      | 58    |        |               |
| qnr A   |                      | 58    |        |               |
|         | Extension            |       | 55 sec |               |
|         | Final extension      |       | 5 min  |               |

### Isolated and Identification of Lactobacillus casei

L.casei were collected from a variety of food sources, including dairy products and aged cheese (ripened cheese). Then, samples were cultured on a selective medium (de Man Rogosa and Sharpe agar, MRS agar) and incubated anaerobically at 37°C for 48 h (Zhang et al., 2020). Following the incubation time, Microscopic examination was done Biochemical tests and Molecular detection.

### Antagonism activity of L. casei against pathogenic bacteria

The inhibitory activity of Lactobacillus casei and its cell-free filtrate against antibiotic-resistant bacterial isolates was evaluated using the well diffusion method on Mueller-Hinton agar. Pathogens were diffused at a concentration of 0.5 McFarland, and 50 µL of the extract was added to 5 mm diameter wells, with two duplicates per sample. After the plates were incubated for 24 hours at 37°C, the inhibitory zone was clculated using a rule r(Divyashree et al., 2021 ).

### Statistical analysis

Data were assessed for any significant differences using a one and two- way ANOVA, when possible. Results were presented as  $M \pm S.D$ . The accepted level of significance was set at  $P \leq 0.05$ , utilizing Mini Tab statistical software version 17 for the analysis, PA, USA, was used for conducting the statistical analysis.

## RESULTS

### Identification of bacterial isolates


Cultivated samples showed that 124 bacterial isolates were distributed into 83 (66.94%) from acute UTIs and 41(33.06%) from renal failure. Distribution of microbes showed that *E. coli* was 31 (37%), *K. pneumoniae* 28 (34%) and *P. aeruginosa* at (11%). The prevalence of *Enterobacter cloacae* and *Morganella morganii* accounted for 6% and 1%, respectively, whereas Gram-positive *Staphylococcus* spp. and *Streptococcus* spp. accounted for 6% and 5% of the cases, respectively. Identification of bacteria by culturing on Blood agar, MacConkey, Eosin Methylene Blue Agar and Cetrimide Agar. Microscopic examination was carried out using biochemical tests and API strip devices.

### Antibiotic susceptibility testing (AST):


Antibiotics susceptibility of, The results of the susceptibility ESBL-producing strains of *E. coli*, *K. pneumoniae*, and *P. aeruginosa* testing showed a clear variation in resistance among the three bacterial species studied. For instance *E. coli* isolates exhibited high susceptibility to carbapenems (100%) for Ertapenem and Meropenem, with broad resistance to second-generation and third-generation cephalosporins ranging between 80% and 90%. Regarding the *K. pneumoniae* isolates demonstrated a more complicated resistance, with resistance to cephalosporins reaching 70% and ampicillin/clavulanic acid reaching 60%. Whereas, *P. aeruginosa* exhibited the highest levels of resistance, including total resistance to ampicillin/clavulanic acid, up to 40% resistance to carbapenems, and restricted sensitivity to current drugs such ceftazidime/avibactam.

### Molecular Detection of genes encoded for Beta Lactamase Enzymes:


The data obtained from the PCR method for detecting beta-lactam resistance genes (*bla* SHV, *bla* TEM, *bla* CTX-M, and *qnrA*) in *K. pneumoniae*, *E. coli* and *P. aeruginosa* revealed significant differences among the species. *K. pneumoniae* isolates exhibited seven occurrences of the *bla* CTX-M gene, six carried the *bla* SHV gene, and only three contained the *bla* TEM gene Figure 1. In contrast, two isolates of *P. aeruginosa* were found to harbor both the *bla* TEM and *qnrA* genes, while *bla* CTX-M and *bla* SHV genes were identified in four isolates of *P. aeruginosa* Figure 2. The results of *E. coli*, showed that just four isolates were positive for the *bla* TEM gene despite thorough screening for all genes; the remaining genes were entirely absent from the remaining isolates of this species. As shown in Figure 3.




**Figure1:** Electrophoresis of PCR Amplicons of (A) blaCTX-M, (B) blaSHV and (C) bla-TEM from *Klebsiella pneumoniae* utilising a 1.5% Agarose Gel at 70 V. (Source: Authors)



**Figure 2:** Electrophoresis of PCR Amplicons of (A) blaCTX-M, (B) bla SHV, (C) blaTEM and (D) qnrA genes from *P. aeruginosa* applying a 1.5% Agarose Gel at 70 V. (Source: Authors)



**Figure3:** Electrophoresis of PCR Amplicons of blaTEM from *Escherichia coli* utilizing a 1.5% Agarose Gel at 70 V. (Source: Authors)




**Figure4:** Electrophoresis for PCR Amplicons of Diagnostic Gene from *L. casei*. (Source: Authors)

#### Diagnosis of Lactic Acid Bacteria (*Lactobacillus casei*)


Samples were cultured on a selective medium (de Man Rogosa and Sharpe agar, MRS agar) and incubated anaerobically at 37°C for 48 h. Following the incubation time, Microscopic examination was done Biochemical tests and Molecular detection as in Figure 4.

#### Antagonistic Activity of *L. casei* against Bacterial Pathogens


Antagonistic activity of *Lactobacillus* isolated from dairy products and aged cheese was evaluated using strains of *L. casei* against the isolated bacterial pathogen isolated from renal failure and acute UTIs. The findings demonstrated that *L. casei* isolates might inhibit the activity of multidrug-resistant clinical pathogens, such as *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, and *Escherichia coli*. On the other hand, statistical analysis did not show any significant differences ( $P < 0.05$ ) attributable to the different sources of lactic acid bacteria isolation (cheese and Activia) or as a result of the different laboratory application methods used (cell-free supernatant method and direct method) against the bacteria isolates.



**Figure 5:** The antagonism activity (the bacterial-free supernatant and direct method) of *L. casei* isolated from cheese and activia against *P. aeruginosa* identified from the urine samples. Columns having the same letters revealed no significant differences ( $P \geq 0.05$ ). (Source: Authors)



**Figure 6 :** The antagonistic activity of *L. casei*, isolated from cheese and Activia, against *E. coli* identified in urine samples was assessed using the cell-free supernatant and direct methods. Columns that share the same letters indicate no significant differences ( $P \geq 0.05$ ). (Source: Authors)



**Figure 7 :** The antagonistic activity of *L. casei*, isolated from cheese and Activia, against *K. pneumoniae* identified in urine samples, was assessed using both the cell-free supernatant and direct methods. Columns that share the same letters indicate no significant differences ( $P \geq 0.05$ ). (Source: Authors)

## DISCUSSION

Acute UTIs are a risk factor for infections in general due to the various immunological alterations described, and for UTIs specifically because of the comorbidities, advanced age and blockage of the urinary tract. However, *E. coli* is the most frequent cause of UTIs in this group of patients, and those with diabetic nephropathy, nephrotic syndrome, autosomal dominant polycystic disease, urolithiasis, and immunosuppressive medication appear to be at the most risk (Dicu-Andreescu et al., 2022). The findings of this study indicate that patients with chronic kidney disease (CKD) may be at a greater risk for infections, such as urinary tract infections, compared to individuals without the condition, which is consistent with the findings of Elsayed et al. (2025), demonstrated that *E. coli* was the most common pathogen in UTIs among our patients with CKD, followed by *K. pneumoniae* and other Gram-negative organisms. The most frequent cause of UTIs is uropathogenic *E. coli*. Changes in colonization, attachment, invasion, and intracellular replication to infiltrate the urothelium and survive intracellularly are characteristics of the adaptive evolution of UPEC (De Gaetano et al., 2023). The outer membrane of Gram-negative bacteria contains lipopolysaccharides, commonly known as endotoxins, particularly in pathogenic strains like *K. pneumoniae*. These components, along with a substantial extracellular polysaccharide layer called a capsule, play a crucial role in protecting the bacteria from the innate defenses of the host (Abbas et al., 2024). Antibiotics susceptibility of ESBL-producing strains of *E. coli* isolates exhibited high susceptibility to carbapenems (100%) for Ertapenem and Meropenem, with broad resistance to second- and third-generation cephalosporins ranging between 80% and 90%.

Supporting this observation, ESBL-producing strains of *E. coli* exhibited very high resistance rates across most beta-lactams and cephalosporins; isolates were resistant to ceftriaxone and cefuroxime (Mir et al., 2025). While *K. Pneumoniae* isolates demonstrated a more complicated resistance, with resistance to cephalosporins reaching 70% and ampicillin/clavulanic acid reaching 60%. This finding is conceptually consistent with the local study conducted in Baghdad, Iraq Razooqi Al-Aajem et al., (2021) where *K. pneumoniae* exhibited the highest levels of resistance to Cefepime (86.11%), Cefazidime (80.56%), Piperacillin (75.0%), and Aztreonam (69.44%). In contrast to the previous findings, 90% of the isolates showed complete susceptibility to gentamicin, while 80% were susceptible to amikacin and trimethoprim/sulfamethoxazole. Additionally, 70% of the isolates were susceptible to ertapenem, meropenem, and fosfomycin, whereas 60% exhibited sensitivity to imipenem, nitrofurantoin, and ciprofloxacin. The present study demonstrated resistance to cephalosporins among all isolates, confirming the findings of Cristea (2017). This study reported high resistance levels in *Klebsiella* spp. strains tested against cephalosporins, with 71.43% resistance to cefazoline and 75% resistance to cefuroxime. Resistance levels staying below 20%, Imipenem 84.5% and Amikacin 79.6% had the highest susceptibility rates indicating their high efficacy against *K. pneumoniae*. Moreover, Piperacillin and Meropenem had moderate activity (around 70% susceptibility). However, *P. aeruginosa* demonstrated the highest levels of resistance, exhibiting total resistance to ampicillin/clavulanic acid, up to 40% resistance to carbapenems, and limited sensitivity to current drugs such as ceftazidime/avibactam. The present findings align with Dadjo et al. (2025), who demonstrated that *P. aeruginosa* isolated from patients with chronic kidney disease exhibited a significantly higher ciprofloxacin resistance rate. Efflux-mediated resistance to quinolones is well known. The most frequent mechanism of high-level resistance is caused by chromosomal mutations within a brief DNA sequence known as the quinolone resistance-determining regions in one or more of the genes encoding the type II topoisomerases for both Gram-positive and Gram-negative organisms (Miranda et al., 2022).

The results showed that the three isolates of *K. pneumoniae* were carried bla-TEM compared to 7 and 6 isolates were possess that bla-CTX-M and bla-SHV, respectively.  $\beta$ -lactamases, specifically the CTX-M-type extended-spectrum  $\beta$ -lactamases, represent a unique and rapidly expanding gene family. Mobile genetic elements, such as ISEcp1, facilitate the mobilization of the bla-CTX-M genes, transferring them to conjugative plasmids. This process contributes to the widespread distribution of these genes among various bacterial species. This transfer not only enhances the spread of antibiotic resistance among bacterial populations but also poses a significant challenge to public health. As these genes proliferate, the effectiveness of  $\beta$ -lactam antibiotics diminishes, leading to treatment failures and increased morbidity (Yu et al., 2024). However, two isolates of *P. aeruginosa* were identified to carry the bla-TEM and qnrA genes, while the blaCTX-M and blaSHV genes were detected in four isolates of *P. aeruginosa*. The primary cause of *P. aeruginosa* resistance to antibiotics, mainly cephalosporins and penicillin, is the ESBLs. The main ESBL genes responsible for this kind of resistance are blaCTX-M (Castanheira et al., 2021). Furthermore, bacterial microevolution may be caused by the accumulation of mutations in their DNA. Under these circumstances, strains are more likely to emerge as new bacterial variants that alter the expression of some virulence factors and increase the profile of antibiotic resistance. These bacterial variants may also exhibit novel cellular and metabolic morphologies that improve their chances of surviving in harsh environments (Flores-Vega et al., 2025). Conversely, four isolates of *E. coli*, showed were positive for the bla TEM gene despite thorough screening for all genes; the remaining genes were entirely absent. Notwithstanding their broad occurrence, the blaCTX-M and bla-SHV genes were completely absent from the remaining investigated isolates. These results clearly indicate that these specific resistance genes may not be universally prevalent among all strains, indicating potential variations in antibiotic resistance profiles. According to the study conducted by Ahmed and Hawezy (2023), some isolates may appear to be resistant to antibiotics without actually having these genes because they rely on complementary mechanisms such as active expulsion or altering cell membrane permeability, which supported the present results. Similarly, Goudarzi et al. (2015), found that none of the bacterial isolates had qnrA or qepA and qnrB was the most prevalent qnr gene.

These results highlight a concerning trend in antibiotic resistance, particularly in clinical settings where these pathogens are frequently encountered. Addressing this issue will require on going surveillance and the development of alternative treatment strategies to effectively manage infections caused by resistant strains. The current findings closely agree with those of Fateh et al. (2024), which demonstrate that the average diameter of the inhibition zone produced by *L. casei* isolates against *E. coli* bacteria was 19.8 mm using the agar well diffusion method. As a researcher confirmed by Algroom (2023), *L. casei* successfully suppressed the *E. coli* pathotype. Probiotics have been shown in numerous studies to reduce the growth of a variety of illnesses. Due to live cells being able to stick to each other, they can block pathogenic microbes from colonizing them, thus preventing superiority (Alshatari and Ziarno, 2026). *L. casei* inhibits *K. pneumoniae* that is resistant to multiple drugs and was isolated from urinary catheters. *L. casei* also creates additional metabolites that

inhibit other bacteria in addition to compounds that resemble bacteriocin (Reza, 2019 ). The antimicrobial activity of the CSF from *L. casei*, which showed growth inhibition against strains *E. coli* and *K. pneumoniae* are in agreement with the present data (Rocha Ramírez et al., 2023). Biofilm formation and dispersion, particularly in the presence of oxidative elements like hydrogen peroxide, alongside the potential presence of proteins with bacteriocin, have been reported to contribute to the generation of organic acids. This may frequently explain the inhibitory activity of *Lactobacillus* strains against *E. coli*. Proteinaceous substances like bacteriocin and lactic, acetic, and propionic acids play a crucial role in inhibiting the growth of pathogenic bacteria (Divyashree et al., 2021). The growth of *P. aeruginosa* is significantly inhibited by CFS from *L. casei* strains. Hydrogen peroxide ( $H_2O_2$ ) can act as a precursor to the production of bactericidal free radicals, such as superoxide ( $O_2^-$ ) and hydroxyl ( $OH^-$ ) radicals, which can damage DNA, and peroxidation of membrane lipids increases the permeability of the membrane. *Lactobacillus casei* is a probiotic bacterium that balances intestinal microbiota, controls intestinal diseases and affects the cellular immune response (Qin et al., 2022). Probiotics reduce pathogenic adherence to mucosal surfaces and colonization, hence competitively eliminating opportunistic pathogens. Probiotics' antibacterial action, which is provided by their metabolic byproducts (Aditya et al., 2020).

## CONCLUSION

Different genera and species of the microbial community were identified, notably with a prevalence of *E. coli*. Moreover, most bacterial isolates were found to be resistant to various antibiotics, in particular *P. aeruginosa*, necessitating alternative treatments to manage their growth. Additionally, there is variation in the results obtained from both the phenotype and genotype methods. This suggests that there may be additional genes not explored in the current study that could be responsible for the antibiotic resistance observed in these bacteria. In this particular context, *Lactobacillus casei* revealed strong antagonism against most of the tested bacterial pathogens, highlighting its potential application in new functional probiotic products for treating these pathogens.

**Sources of funding:** No grant from a governmental, private, or nonprofit organisation was obtained for this study.

**Contribution of the author:** Each author made an equal contribution to the research.

**Conflict of interest:** non

## Ethical Approval

Before each patient was included in the study, informed consent was acquired from both the hospital administration and the patients themselves. To guarantee complete comprehension of the process, all procedures were thoroughly described to the patients or their guardians prior to sample collection. Patients had the option to decline participation in the study or refuse sample collection, and participation was completely optional.

## REFERENCES

- 1-Abbas, R., Chakkour, M., Zein El Dine, H., Obaseki, E. F., Obeid, S. T., Jezzini, A., ... & Ezzeddine, Z. (2024). General overview of *Klebsiella pneumoniae*: epidemiology and the role of siderophores in its pathogenicity. *Biology*, 13(2), 78. <https://doi.org/10.3390/biology13020078>
- 2-Aditya, A., Peng, M., Young, A., & Biswas, D. (2020). Antagonistic mechanism of metabolites produced by *Lactobacillus casei* on lysis of enterohemorrhagic *Escherichia coli*. *Frontiers in Microbiology*, 11, 574422. <https://doi.org/10.3389/fmicb.2020.574422>
- 3-Ahmed, K. K., & Hawezzy, A. A. (2023). Molecular detection of *bla*TEM, *bla*SHV, and *bla*CTX-M genes among Uropathogenic *Escherichia coli* isolated from cases with urinary tract infection in Erbil city-Iraq. *Diyala Journal of Medicine*, 25(1), 67-78. <https://doi.org/10.26505/djm.v25i1.1015>
- 4-Algroom, R. (2023). The antimicrobial and antibiofilm activity of *Lactobacillus salivarius* and *Lactobacillus casei* against *Escherichia coli*. The antimicrobial and antibiofilm activity of *Lactobacillus salivarius* and *Lactobacillus casei* against *Escherichia coli*. <http://doi.org/10.26789/AEB.2023.01.003>
- 5-Alshatari, S. S., & Ziarno, M. (2026). Probiotic-driven competitive exclusion in the human gut: A meta-analysis of microbial diversity and pathogen suppression. *Nutrients*, 18(5), 796. <https://doi.org/10.3390/nu18050796>

- 6-Castanheira, M., Simner, P. J., & Bradford, P. A. (2021). Extended-spectrum  $\beta$ -lactamases: an update on their characteristics, epidemiology and detection. *JAC-antimicrobial resistance*, 3(3), dlab092. <https://doi.org/10.1093/jacamr/dlab092>
- 7-Coutinho, G. M. D. M., Silva, E. C. D., Campanharo, C. R. V., Belasco, A. G. S., Fonseca, C. D. D., & Barbosa, D. A. (2022). Infecção do trato urinário em pacientes com doença renal crônica em tratamento conservador. *Revista Brasileira de Enfermagem*, 75, e20210065. <https://doi.org/10.1590/0034-7167-2021-0065>
- 8-Cristea, O. M., Avrănescu, C. S., Bălăsoiu, M., Popescu, F. D., Popescu, F., & Amzoiu, M. O. (2017). Urinary tract infection with *Klebsiella pneumoniae* in Patients with Chronic Kidney Disease. *Current health sciences journal*, 43(2), 137. doi: 10.12865/CHSJ.43.02.06
- 9-Dadjo, B. S., Mbaveng, A. T., Kengne, M. F., Tsobeng, O. D., Fonjou, G. D., & Kuete, V. (2025). Prevalence of ESBL resistance genes and fecal carriage of multidrug-resistant *Pseudomonas aeruginosa* isolates from patients with chronic kidney disease at the Laquintinie Hospital in Douala, Littoral Region, Cameroon. *Journal of Infection and Public Health*, 18(2), 102651. <https://doi.org/10.1016/j.jiph.2024.102651>
- 10-De Gaetano, G. V., Lentini, G., Famà, A., Coppolino, F., & Beninati, C. (2023). In vivo role of two-component regulatory systems in models of urinary tract infections. *Pathogens*, 12(1), 119. <https://doi.org/10.3390/pathogens12010119>
- 11-Dicu-Andreescu, I., Penescu, M. N., Căpușă, C., & Verzan, C. (2022). Chronic kidney disease, urinary tract infections and antibiotic nephrotoxicity: are there any relationships?. *Medicina*, 59(1), 49. <https://doi.org/10.3390/medicina59010049>
- 12-Divyashree, S., Anjali, P. G., Somashekaraiah, R., & Sreenivasa, M. Y. (2021). Probiotic properties of *Lactobacillus casei*-MYSRD 108 and *Lactobacillus plantarum*-MYSRD 71 with potential antimicrobial activity against *Salmonella paratyphi*. *Biotechnology Reports*, 32, e00672. <https://doi.org/10.1016/j.btre.2021.e00672>
- 13-Divyashree, S., Anjali, P. G., Somashekaraiah, R., & Sreenivasa, M. Y. (2021). Probiotic properties of *Lactobacillus casei*-MYSRD 108 and *Lactobacillus plantarum*-MYSRD 71 with potential antimicrobial activity against *Salmonella paratyphi*. *Biotechnology Reports*, 32, e00672. <https://doi.org/10.1016/j.btre.2021.e00672>
- 14-Elsayed, M. M., Elzayat, D. M., Mekawy, R. M., Mahdy, S. M., Imam, S. T., El-Hassan, H. A., ... & Gawad, M. A. (2025). Urinary tract infection in patients with chronic kidney disease: a retrospective observational study at outpatient nephrology clinics. *Journal of The Egyptian Society of Nephrology and Transplantation*, 25(2), 49-56. DOI: 10.4103/jesnt.jesnt\_26\_24
- 15-Fateh, M., Forohi, F., & Rafiee, F. (2024). The antimicrobial effect of *Lactobacillus casei* against *Klebsiella pneumoniae* and *Escherichia coli* isolated from urinary samples. *Journal of Advanced Biomedical Sciences*, 14(2), 94-103. <http://dx.doi.org/10.18502/jabs.v14i2.15749>
- 16-Flores-Vega, V. R., Partida-Sanchez, S., Ares, M. A., Ortiz-Navarrete, V., & Rosales-Reyes, R. (2025). High-risk *Pseudomonas aeruginosa* clones harboring  $\beta$ -lactamases: 2024 update. *Heliyon*, 11(1). <https://doi.org/10.1016/j.heliyon.2024.e41540>
- 17-Goudarzi, M., Azad, M., & Seyedjavadi, S. S. (2015). Prevalence of Plasmid-Mediated Quinolone Resistance Determinants and OqxAB Efflux Pumps among Extended-Spectrum  $\beta$ -Lactamase Producing *Klebsiella pneumoniae* Isolated from Patients with Nosocomial Urinary Tract Infection in Tehran, Iran. *Scientifica*, 2015(1), 518167.
- 18-Habboush, Y., & Guzman, N. (2023). Antibiotic resistance In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513277/>
- 19-Ibrahim, O. M., El-Hawary, A. S., El-Sehrawy, M. H., & Ismail, M. K. (2024). Probiotic Lactic acid bacteria: A Promising alternative approach to control human threats. *Al-Azhar Journal of Agricultural Research*, 49(1), 95-107. <https://doi.org/10.21608/ajar.2024.246914.1291>
- 20-Li, Y., Chen, L., Yang, X., Cui, H., Li, Z., Chen, W., ... & Zhu, M. (2025). Dynamic association of serum albumin changes with inflammation, nutritional status and clinical outcomes: a secondary analysis of a large prospective observational cohort study. *European Journal of Medical Research*, 30(1), 679. <https://doi.org/10.1186/s40001-025-02925-5>
- 21-Liu, P., Hu, P., Jin, M., Sun, W., Wu, J., Tang, Y., ... & He, H. (2025). Compound probiotics alleviate hyperuricemia-induced renal injury via restoring gut microbiota and metabolism. *BMC microbiology*, 25(1), 280. <https://doi.org/10.1186/s12866-025-04012-5>
- 22-Mir, S. S., Ali, E., Alghamdi, S. A. A., Alghamdi, N. M., Alharbi, R. A., Sindi, A. A., & Zaeri, A. A. (2025). Antimicrobial Resistance in Urinary Tract Infections Among Patients with and Without Renal Comorbidities: A Retrospective Study from Al-Baha, Saudi Arabia. *Pathogens*, 14(12), 1297. <https://doi.org/10.3390/pathogens14121297>

- 23-Miranda, C. D., Concha, C., Godoy, F. A., & Lee, M. R. (2022). Aquatic environments as hotspots of transferable low-level quinolone resistance and their potential contribution to high-level quinolone resistance. *Antibiotics*, 11(11), 1487. <https://doi.org/10.3390/antibiotics11111487>
- 24-Mirkalantari, S., Masjedian, F., Irajian, G., Siddig, E. E., & Fattahi, A. (2020). Determination of the frequency of  $\beta$ -lactamase genes (bla SHV, bla TEM, bla CTX-M) and phylogenetic groups among ESBL-producing uropathogenic *Escherichia coli* isolated from outpatients. *Journal of Laboratory Medicine*, 44(1), 27-33. <https://doi.org/10.1515/labmed-2018-0136>
- 25-Młynarska, E., Budny, E., Saar, M., Wojtanowska, E., Jankowska, J., Marciszuk, S., ... & Franczyk, B. (2024). Does the composition of gut microbiota affect chronic kidney disease? Molecular mechanisms contributed to decreasing glomerular filtration rate. *International Journal of Molecular Sciences*, 25(19), 10429. <https://doi.org/10.3390/ijms251910429>
- 26-Monroy-Higuera, J., Angulo-Zamudio, U. A., Leon-Sicairos, N., Flores-Villaseñor, H., Velazquez-Roman, J., Ruiz-Trejo, E., ... & Canizalez-Roman, A. (2026). Epidemiological and Clinical Characteristics Associated with Antimicrobial-Resistant Urinary Tract Infections in Outpatient and Inpatient Settings: A Retrospective Study from Northwestern Mexico. *Pathogens*, 15(1), 92. <https://doi.org/10.3390/pathogens15010092>
- 27-Ong, A., Mahobia, N., Browning, D., Schembri, M., & Somani, B. K. (2021). Trends in antibiotic resistance for over 700,000 *Escherichia coli* positive urinary tract infections over six years (2014–2019) from a university teaching hospital. *Central European journal of urology*, 74(2), 249. doi: 10.5173/ceju.2021.0053
- 28-Putri, W. A., Setiawan, J., Prastiyanto, M. E., Sofyantoro, F., Siregar, A. R., & Wibowo, A. T. (2025). Emergence of Multidrug Resistance in Urinary Tract Infections Patients Worldwide (1976-2024): Bibliometric Analysis. *The Microbe*, 100523. <https://doi.org/10.1016/j.microb>
- 29-Qin, D., Ma, Y., Wang, Y., Hou, X., & Yu, L. (2022). Contribution of lactobacilli on intestinal mucosal barrier and diseases: perspectives and challenges of *Lactobacillus casei*. *Life*, 12(11), 1910. <https://doi.org/10.3390/life12111910>
- 30-Razooqi Al-Aajem, B. M., Saleem, A. J., & Jasim, H. M. (2021). Detection of extended spectrum beta-lactamase genes (bla-CTX and bla-SHV) and same virulent genes in *K. pneumoniae* isolated from urinary tract infection. *Biochemical & Cellular Archives*, 21(2), 4705. <https://connectjournals.com/03896.2021.21.4705>
- 31-Reza, M. (2019). Preliminary characterization and inhibitory activity of bacteriocin like substances from *Lactobacillus casei* against multi-drug resistant bacteria. *Bangladesh Journal of Microbiology*.
- 32-Rocha-Ramírez, L. M., Hernández-Chiñas, U., Moreno-Guerrero, S. S., Ramírez-Pacheco, A., & Eslava, C. A. (2023). In vitro effect of the cell-free supernatant of the *Lactobacillus casei* strain IMAU60214 against the different pathogenic properties of diarrheagenic *Escherichia coli*. *Microorganisms*, 11(5), 1324. <https://doi.org/10.3390/microorganisms11051324>
- 33-Yu, K., Huang, Z., Xiao, Y., Gao, H., Bai, X., & Wang, D. (2024). Global spread characteristics of CTX-M-type extended-spectrum  $\beta$ -lactamases: a genomic epidemiology analysis. *Drug Resistance Updates*, 73, 101036.
- 34-Zhang, X., Esmail, G. A., Alzeer, A. F., Arasu, M. V., Vijayaraghavan, P., Choi, K. C., & Al-Dhabi, N. A. (2020). Probiotic characteristics of *Lactobacillus* strains isolated from cheese and their antibacterial properties against gastrointestinal tract pathogens. *Saudi Journal of Biological Sciences*, 27(12), 3505-3513. <https://doi.org/10.1016/j.sjbs.2020.10.022>
- 35-Zhou, Y., Zhou, Z., Zheng, L., Gong, Z., Li, Y., Jin, Y., ... & Chi, M. (2023). Urinary tract infections caused by uropathogenic *Escherichia coli*: mechanisms of infection and treatment options. *International journal of molecular sciences*, 24(13), 10537. <https://doi.org/10.3390/ijms241310537>